Obtenga las últimas noticias sobre las acciones de MiMedx Group con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de MDXG

Últimas noticias sobre

MiMedx Group

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

MIMEDX GROUP INC

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

MiMedx Group Inc

Earnings

Press Releases

MIMEDX Announces First Quarter 2025 Operating and Financial Results

Health Care

MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

MIMEDX to Present at the BofA Securities 2025 Healthcare Conference

MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026

MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30

MIMEDX Announces Strategic Collaboration with Vaporox, Inc.

MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall

Akebia Therapeutics

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

BridgeBio Oncology Therapeutics, Inc. - Common Stock

BridgeBio Oncology

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

89bio

Geron

GRAIL

Immunome

NuCana

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

uniQure

Arcus Biosciences

Sionna Therapeutics

ARS Pharmaceuticals

Stoke Therapeutics

Spyre Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Upstream Bio

UroGen Pharma

Zymeworks

Cantor Fitzgerald

Craig-Hallum

HC Wainwright & Co.

Lake Street

Mizuho

Comments

MiMedx Group Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL